Evaluating and implementing CytoSure™ microarrays
How adopting the highest quality microarray technology is far easier than might be expected, following the results of the UK’s National Health Service tender.
With the speed of technological advances in the field of genetics, researchers can gain a host of benefits by continuing to consider the best options available, utilising the latest developments to enhance their work. Switching array platforms, however, might seem both daunting and potentially risky, and yet this can yield many advantages, improving efficiency and generating more insightful data in the most costeffective manner possible.
In line with this, the UK’s National Health Service (NHS) recently put the microarray supply for a consortium of its clinical genetics research laboratories out to tender. The consortium, led by four prominent laboratories located across the country, devised a comprehensive and objective assessment of microarray platforms. In order to assess the quality of the platforms, each laboratory submitted a variety of challenging samples for processing, and as a result of this highly stringent process, Oxford Gene Technology’s (OGT) CytoSure™ ISCA 8x60k platform was selected over a number of alternative array suppliers. Designed in collaboration with the International Collaboration for Clinical Genomics (formerly known as the International Standards for Cytogenomic Arrays [ISCA] Consortium), the array delivers standardised, evidence-based designs, and Sheffield Children’s NHS Foundation Trust was the first of the laboratories to transfer to the OGT platform.
Discussing the smooth transition to OGT’s platform, and how this has enhanced the Sheffield laboratory’s work, Product Manager for CytoSure, Dr Ruth Burton spoke to Kath Smith, Consultant Clinical Scientist at Sheffield Children’s NHS Foundation Trust about her laboratory’s experience.
To read the full white paper please enter your details below:
Before you can download this please fill in some details.